ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
The Mechanistic Role of Gitogenin as a Treatment for Laryngeal Cancer: A Network Pharmacology and Experimental Analysis
Provisionally accepted
- 1Inner Mongolia Minzu University, Tongliao, China
- 2The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Laryngeal cancer (LC) is a significant and persistent therapeutic challenge worldwide. Gitogenin (GIT), a naturally occurring saponin, has demonstrated anticancer activity in lung cancer. However, its potential effects on LC remain unclear. This study aimed to elucidate the therapeutic efficacy of GIT and the mechanisms through which it acts against LC by integrating network pharmacology analysis with experimental validation. Methods: Potential targets of GIT were established using the PharmMapper database, while LC-associated genes were retrieved from the GeneCards database. Common targets between GIT and LC were determined, and the top 20 genes were chosen for protein-protein and gene-gene interaction (PPI and GGI) network construction. Functional enrichment analyses were conducted. Finally, in vitro experiments were performed to validate how GIT affects LC. Results: A total of 96 putative GIT targets for LC were identified. KEGG enrichment identified the PI3K-Akt axis a key regulatory mechanism. In vitro experiments provided confirmation that GIT inhibited LC cell proliferation, viability, migratory activity, and invasion ability by modulating PI3K-Akt signaling. Conclusions: Using network pharmacology and experimental validation, it was demonstrated that GIT exerts potent anticancer effects on LC by targeting the PI3K-Akt axis. The present findings suggest the potential of GIT for treating LC.
Keywords: gitogenin, Laryngeal cancer, Network Pharmacology, PI3K-Akt pathway, therapeutic efficacy
Received: 10 Jul 2025; Accepted: 04 Dec 2025.
Copyright: © 2025 Fu, Guan and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhangwei Hu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.